Common Contracts
4 similar Underwriting Agreement contracts by BiondVax Pharmaceuticals Ltd., Jiuzi Holdings, Inc., Vascular Biogenics Ltd., Wearable Devices Ltd.
Underwriting AgreementUnderwriting Agreement • September 22nd, 2022 • Wearable Devices Ltd. • Computer communications equipment • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • July 15th, 2021 • Jiuzi Holdings, Inc. • Retail-auto dealers & gasoline stations • New York
Jiuzi Holdings, Inc., an exempted company incorporated in the Cayman Islands. (the “Company”), proposes to sell to the underwriters named in Schedule I (the “Underwriters”) to this agreement (the “Agreement”) for which Maxim Group LLC is acting as representative (in such capacity, the “Representative”) an aggregate of (i) [●] ordinary shares, par value $0.001 per share (“Ordinary Shares”) of the Company (the “Firm Shares,”) and (ii) warrants to purchase an aggregate of _____________ Ordinary Shares (the “Firm Warrants”). In addition, the Company proposes to grant to the Underwriters an option to purchase up to an aggregate of (i) [●] additional Ordinary Shares (the “Option Shares” and collectively with the Firm Shares, the “Shares”) and/or (ii) warrants to purchase an aggregate of _____________ additional Ordinary Shares (the “Option Warrants” and collectively with the Firm Warrants, the “Warrants”), each on the terms set forth in Section 2. Each Warrant entitles the holder to purchase
2,500,000 Ordinary Shares and Warrants to Purchase 1,250,000 Ordinary Shares Vascular Biogenics Ltd. EQUITY UNDERWRITING AGREEMENTUnderwriting Agreement • November 5th, 2015 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
Vascular Biogenics Ltd., an Israeli company (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named on Schedule I hereto for whom you are acting as the representative (the “Representative”) (i) an aggregate of 2,500,000 shares (the “Shares”) of the Company’s ordinary shares, NIS 0.01 nominal value (the “Ordinary Shares”) and (ii) warrants of the Company to purchase an aggregate of 1,250,000 Ordinary Shares in the form set forth in Exhibit B (the “Warrants”). The respective amounts of the Shares and Warrants to be so purchased by the several Underwriters are set forth opposite their names on Schedule I hereto. Each Share is being sold together with a Warrant to purchase 0.5 of an Ordinary Share at an exercise price of $7.50 per whole Ordinary Share.
UNDERWRITING AGREEMENT between BIONDVAX PHARMACEUTICALS LTD. and AEGIS CAPITAL CORP., as Representative of the Several UnderwritersUnderwriting Agreement • April 28th, 2015 • BiondVax Pharmaceuticals Ltd. • Biological products, (no disgnostic substances) • New York
The undersigned, BiondVax Pharmaceuticals Ltd., a company formed under the laws of the State of Israel (the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
